Cisplatin-Mitomycin-Vinblastine Regimen

Known as: MVP Regimen 
A regimen consisting of cisplatin, mitomycin and vinblastine used to treat advanced-stage non-small cell lung cancer.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2003
01219922003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
OBJECTIVE To investigate the activity and clinical efficacy of toremifene plus mitomycin, vindesin and cisplatin regimen (MVP) in… (More)
Is this relevant?
2003
2003
PURPOSE A prospective Phase I/II dose escalation study was conducted to determine the maximum tolerated dose (MTD) in three… (More)
Is this relevant?
2003
2003
BACKGROUND To investigate the efficacy of EP regimen combined with split-course hyperfractionated accelerated irradiation for… (More)
Is this relevant?
2002
2002
PURPOSE To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in… (More)
Is this relevant?
2002
2002
BACKGROUND To evaluate the therapeutic effect and acute side-effect of escalated hyperfractionated accelerated radiation therapy… (More)
Is this relevant?
2001
2001
The majority of patients diagnosed with non-small cell lung carcinoma (NSCLC) present with advanced disease and, as such, are… (More)
Is this relevant?
1999
1999
In a prospective randomized study, 287 patients with advanced non-small cell lung cancer (NSCLC) stage IIIb or IV with ECOG… (More)
Is this relevant?
1998
1998
The aim of this randomised trial was to compare the efficacy of bolus versus continuous infusion cisplatin combined with… (More)
Is this relevant?
1992
1992
Cisplatin has many toxic effects; emesis, impairment of renal function, myelosuppression, peripheral neuropathy, ototoxicity and… (More)
Is this relevant?
1992
1992
Between August 1985 and June 1986, 49 previously untreated patients with locally advanced or metastatic non-small-cell lung… (More)
Is this relevant?